Brief: Blueprint Medicines Reports Clinical Data In Developing Targeted Treatment Options For Patients With Systemic Mastocytosis

Blueprint Medicines

11/12/2022 22:53

Dec 11 (Reuters) - Blueprint Medicines Corp  BPMC.O :
    * BLUEPRINT MEDICINES REPORTS CLINICAL DATA HIGHLIGHTING
LEADERSHIP IN DEVELOPING TARGETED TREATMENT OPTIONS FOR PATIENTS
WITH SYSTEMIC MASTOCYTOSIS
    * 95% CONFIRMED OVERALL RESPONSE RATE AND 37% CONFIRMED
COMPLETE
REMISSION RATE IN TREATMENT-NAÏVE PATIENTS WITH SM-AHN
    * ONGOING SURVIVAL BENEFITS, WITH UP TO SIX YEARS OF
FOLLOW-UP, IN
PATIENTS WITH ADVANCED SM FROM EXPLORER TRIAL OF AYVAKIT
    * TOP-LINE, 12-WEEK PART 1 DATA FROM HARBOR TRIAL SHOW
ELENESTINIB
IMPROVED MEASURES OF MAST CELL BURDEN
    * BLUEPRINT MEDICINES - TOP-LINE, 12-WEEK PART 1 DATA FROM
HARBOR
TRIAL SHOW ELENESTINIB IMPROVED MEASURES OF PATIENT-REPORTED
SYMPTOMS IN INDOLENT SM

Source text for Eikon:  ID:nPn3FwS7Ja 
Further company coverage:  BPMC.O 
 ((Reuters.Briefs@thomsonreuters.com;))